HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Prompts OTC Sales Restrictions Across Europe

Executive Summary

Countries across Europe are restricting sales of OTC drugs in response to COVID-19 to maintain supply and counteract stockpiling. The approach varies widely across the region: countries such as Germany and France have introduced strict limits, while others, such as the UK and Ireland, have not ordered official restrictions. HBW Insight presents an analysis of the actions taken by 14 European countries to the upsurge in demand for OTCs.

You may also be interested in...



Learn From Regulatory Innovation During COVID-19, Urges Global Self-Care Industry

The Global Self-Care Federation has published three papers outlining how regulatory flexibility and innovation seen during the cornavirus pandemic can be brought forward to a post-pandemic consmer heathcare sector. 

2020 In Review: HBW Insight’s Five Key Takeaways For The European OTC Industry

HBW Insight extracts five key lessons from 2020, the year the coronavirus pandemic swept its way across Europe. 

Lessons Learned: European Self-Care Industry Will Come Out Of Pandemic Stronger

Europe’s self-care industry has “learned its lessons,” particularly in terms of securing the pharmaceutical ingredient supply chain, and will come out of the coronavirus pandemic stronger, insisted AESGP president Birgit Schuhbauer at the BAH’s High-Level Conference on Future Drug Supply in the European Union.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS149841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel